Tetra Bio-Pharma announced that the company’s investigational new drug involving cannabinoids, QIXLEEF, received guidance to strengthen its nonclinical and toxicological data from the U.S. Food and Drug Administration, which brings the aerosol botanical therapy closer to marketing approval.
The U.S. health regulator on January 13 approved Zoetis Inc,’s once-a-month injection to treat pain in cats with osteoarthritis, a common but difficult-to-diagnose condition that affects the joints in older cats.
Drugmaker Biohaven Pharmaceutical said on December 6 the company’s intranasal spray to treat migraine showed rapid pain relief and met the main goals in a late-stage study.
BioSpace reviews some of the more interesting recently published scientific studies, including whether the Covid-19 virus relieve pain.
Concentric Analgesics Inc. announced today that the clinical-stage biopharmaceutical company received Breakthrough Therapy designation from the U.S. Food and Drug Administration for CA-008 in post-surgical pain.
The U.S. Food and Drug Administration approved Kala Pharmaceuticals Inc.’s treatment for reducing inflammation and pain following an eye surgery.
Anthem Inc. partnered with Walmart Inc. to launch a program in January 2019 that will allow the health benefit company’s Medicare Advantage plan customers to purchase over-the-counter medications from the retailer’s stores and website.
The Australian Competition and Consumer Commission said the ACCC is taking local units of GlaxoSmithKline and Swiss healthcare company Novartis to court over false or misleading representations in the marketing of pain relief products.
Durect Corporation inked a development and commercialization deal with Sandoz AG, a division of Novartis AG, totaling around $293 million.
Only some doses of Trevena’s experimental opioid painkiller were found as effective as morphine in two late-stage studies, though the drug met its main study goals.